The New Transparency: What Will it Mean for the Practice of Medicine?

David J. Rothman, Ph.D.

Bernard Schoenberg Professor of Social Medicine
Columbia College of Physicians and Surgeons
President
Institute on Medicine as a Profession

David J. Rothman, PhD


No Financial Conflicts of Interest to Disclose

David Rothman is serving as a consultant and expert witness for the office of the Attorney General of the State of Texas in its litigation against Johnson & Johnson related to Risperidone.

THE THEORY OF TRANSPARENCY

"Sunlight is said to be the best of disinfectants; electric light is the most efficient policeman."

(Justice Louis Brandeis)



- People behave best when closely watched
- The concept first took hold in government, went on to affect industry, then other social institutions, and now, finally, is beginning to take hold in medicine.


TRANSPARENCY IN MEDICINE

OUR SUBJECTS TODAY:

- A brief analysis of the history of transparency
- How transparency spread to medicine
- What are its implications for physicians and patients?

THE FREEDOM OF INFORMATION ACT (FOIA)

 The foundation stone of government transparency.



- Lyndon Johnson signed it into law on July 4, 1966, grudgingly and with no formal signing ceremony.
- He himself had numerous objections as did many federal agencies. They feared that:
 - Republicans would use it to their political advantage
 - National security would be jeopardized
 - Journalists would rummage through files in search of dirt
 - Citizen requests would overwhelm the bureaucracy

TRANSPARENCY

- Transparency is <u>contagious</u>. Following on FOIA, federal and state governments enacted **sunshine laws** to open up administrative meetings once held behind closed doors.
- Transparency is <u>controversial</u>: Wikileaks.
- Transparency is global. Some 90 countries around the world, including China, have FOIAtype legislation.

TRANSPARENCY

Transparency produces data as well as information.

- Automobile manufacturers must put stickers on the windows of new cars detailing roll-over test results.
- Food manufacturers and chain restaurants must report fat, calorie, sugar, and salt content of their products.
- Not-for-profit organizations must make public salaries of their chief executives and five highest paid earners.
- Public companies must provide profit, loss, and expenditure data and describe fully potential risks and returns when they float new stocks.

THE LIMITS OF TRANSPARENCY



THE LIMITS OF TRANSPARENCY (Cont.)

From the Would-Be Consumers of the Information:

- Very few people read/understand the food labels.
- Even fewer people read/understand the fine print in corporate reports.
- And even fewer people than that consult Guidestar to learn about salaries.



A more complicated and problematic assignment. There are important competing principles:

Physician confidentiality-- going back to the Hippocratic Oath.



Patient privacy-- enshrined in the 1996 Health Insurance Portability and Accountability Act (HIPAA).



And yet, changes have come to medicine as well.

The Medical Chart:

Once considered the exclusive preserve of health care providers. But as the concept of patient autonomy took hold in the 1980s, patients and their families increasingly, and successfully, demanded to see the chart. Eventually, HIPAA guaranteed their right to do so.

Medical Outcomes

New York was among the first states to require hospitals to release the results of coronary artery by-pass procedures by institutions and by surgeons.

OUTCOMES BY SURGEON

	Isolated CABG							Isolated CABG, or Valve or Valve/CABG	
	Cases	No of Deaths	OMR	EMR	RAMR	95% CI for RAMR	Cases	RAMR	
NY Methodist Hospital									
#Lee L Y	150	3	2.00	2.22	1.77	(0.36, 5.16)	205	2.54	
#Tortolani A	217	1	0.46	2.00	0.45	(0.01, 2.51)	291	2.50	
All Others	10	0	0.00	1.14	0.00	(0.00,62.82)	10	0.00	
Total	377	4	1.06	2.07	1.01	(0.27, 2.58)	506	2.50	
NYP- Columbia Presby.									
Argenziano M	105	4	3.81	1.62	4.61	(1.24,11.81)	312	3.95	
#Chen J M						(. , .)	1	0.00	
##D Alessandro D A	2	0	0.00	1.72	0.00	(0.00,100.0)	3	0.00	
Mosca R S	1	0	0.00	0.38	0.00	(0.00,100.0)	5	30.48	
Naka Y	232	8	3.45	1.75	3.87	(1.67, 7.63)	446	4.66	
Oz M	252	2	0.79	1.23	1.26	(0.14, 4.55)	715	3.83	
#Quaegebeur J						(. , .)	10	0.00	
Smith C	255	5	1.96	1.05	3.65	(1.18, 8.51)	777	3.15	
Stewart A S	263	7	2.66	2.23	2.34	(0.94, 4.81)	528	3.74	
All Others	36	2	5.56	2.12	5.13	(0.58,18.51)	98	6.59	
Total	1146	28	2.44	1.59	3.01 *	(2.00, 4.35)	2895	3.95 *	

Other Medical Outcomes

Rates of in-patient infections

Rates of medical error

Rates of patient falls

WHO USES THE DATA?

An Open question.

Named Individuals do

Named Institutions do

Very doubtful if patients/consumers do

BRINGING TRANSPARENCY TO MEDICINE: FINANCIAL DATA ON PHYSICIANS AND COMPANIES

Over the past five years, a revolution has occurred in the disclosure of doctor/company financial arrangements.

BRINGING TRANSPARENCY TO MEDICINE: FINANCIAL DATA ON PHYSICIANS AND COMPANIES

Legislative Initiatives: State and Federal

 Six states now require drug companies to report gifts and payments to physicians

Many others are considering similar bills

STATE INITIATIVES



FEDERAL INITIATIVE



Physician Payments Sunshine Act of 2009:

To amend title XI of the Social Security Act to provide for transparency in the relationship between physicians and manufacturers of drugs, devices, biological, or medical supplies for which payment is made under Medicare, Medicaid, or SCHIP.

INDUSTRY DISCLOSURE

- Over the past few years, 14 companies began posting payments to health professionals and organizations on their websites.
- As part of settlements to resolve prosecutions, the device companies Biomet, DePuy, Smith & Nephew, Stryker, and Zimmer agreed to disclose their payments to "consultants."
- Pharmaceutical companies have also agreed to disclose:

PRO PUBLICA



Home

Our Investigations

Tools & Data

Reporting Network

Blog About Us



Dollars for Docs

What Drug Companies are Paying Your Doctor

Top Earners

Story: Who's on Pharma's Top-Paid List?

In October 2010, ProPublica identified 384 healthcare providers who earned more than \$100,000 total from one or more of the seven companies that have disclosed payments in 2009 and early 2010. We matched the payee records with licensed doctors and registered nurses in the states listed. When a match could not be found, for example when a recipient was a pharmacist, we used other sources to confirm their identities.

The payments are listed as we compiled them in October 2010 and so the displayed total may not be up-to-date. Do a search to find the recipient's latest payments.

See more details about the compilation of this list.

If you are a listed practitioner and believe you do not belong in this database, please contact us at ornstein.weber@propublica.org.

Name	\$	State \$	Certification ‡	Payments	‡
	N	Nev.		GSK	\$209,400
Firhaad Ismail			Internal Medicine; Endocrinology and	Eli Lilly	\$81,608
			Metabolism	Merck	\$12,550
			Trockwitty towns.		\$303,558
	Tenn.			GSK	\$168,800
Stephen H. Landy		T	N	Cephalon	\$131,300
Stephen H. Landy		renn.	Neurology	Merck	\$2,025
					\$302,125
	Tenn.	Tenn.		GSK	\$151,700
Samuel Dagoge Jack			Internal Medicine; Endocrinology, Diabetes and Metabolism	Eli Lilly	\$98,987
Samuel Dagogo-Jack				Merck	\$6,325
					\$257,012

- For the first time, full and accurate data on company payments to physicians and health care organizations, independent of individual disclosures.
- No one has disputed the accuracy of company figures as reported on websites or to states.
- There is confusion about terms and 1099 forms.
- What you take/receive is now public information.

Will Transparency Change Practices?

Perhaps Not.

- Very few resignations from Speakers' Bureaus as companies post payouts
- Suggestions that seeing colleagues' compensation will drive up your own demands
- Consumers do not use databases very well
- Consulting the databases, which are not now consolidated, is cumbersome

Will Transparency Change Practices?

More likely Yes: why trust if you can verify?

- Academic Medical Center use
- Professional Medical Associations use
- Journal use
- Student use
- FDA/NIH use
- Media use
- Educated consumer use

Transparency will change practice.

Disclosure will not be a license, but will prompt disqualification.

Data that gifts, consultancies, honoraria, and other payments bias the recipient is overwhelming.

Therefore, appointments to lecture, join formulary committees, serve on FDA advisory committees or NIH study groups, are likely to be affected.

A possible emergence of a two-track system:

- The **Entrepreneur** for whom transparency provides public recognition of financial success.
- The Professional who accepts no personal industry funding, so as to pursue leadership positions within the profession.